Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...
Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...
Eli Lilly has amassed a market value nearing a trillion dollars based on the assumption that demand for its new weight-loss ...
The FDA became aware of the problem after a patient submitted a complaint to the regulator that a vial of semaglutide from ...
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people ...
Eli Lilly, the maker of the popular weight loss drug Zepbound, revealed a "shocking first miss" during its most recent ...
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
I’d been wanting to lose weight for a while and the traditional methods just weren’t working for me. Deprive myself of carbs for a week and I would drop a measly 2lb. Hire a personal trainer – the ...
There’s been lots of attention on type 2 diabetes drugs recently, especially since they might also be able to support weight ...
Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per share, ...